We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Quantitative Strategy for Pooling COVID-19 Tests Could Detect Outbreaks Early

By LabMedica International staff writers
Posted on 09 Mar 2021
Print article
Illustration
Illustration
Scientists have developed a new model to evaluate the performance of a group testing strategy for the SARS-CoV-2 virus, which involves pooling samples from multiple individuals in order to conduct a single RT-PCR test on the whole group.

The theoretical study by scientists at Université Grenoble Alpes (Grenoble, France) accounts for both dilution effect and the detection limits of the RT-PCR test, in an effort to assess the number of potential false negatives based on pooled sample size, to optimize group size thereby minimizing epidemic risk, and finally to more accurately determine the number of contaminated individuals within a given population.

The principle of group testing is simple mathematically speaking: rather than test one hundred samples (one per individual), they can be pooled into ten groups of ten, with only one test for each group. If the test result for a group is positive, then at least one of the group’s samples contains the infectious agent. Conversely, a negative result should, in principle, indicate that none of the combined samples contains the infectious agent. Sample pooling method can reduce the cost can accelerate screening campaign, yet pooling can result in a false positive result whenever mixing samples involves a too large dilution - namely when the quantity of the virus in the tested sample falls below the test’s level of detection.

To assess the efficiency of screening based on a group testing strategy, the researchers who are members of the MODCOV19 platform have developed a mathematical model that estimates this dilution effect based on sample group size. Their model can quantify the reduction of sensitivity for tests, hence the capacity of tests with larger or smaller groups to detect the presence of a contagious individual. Unlike methods that try to minimize the number of tests needed to establish an individual diagnostic for the contaminated individual or individuals, the model’s central aim is to help optimize a collective screening strategy: how best to optimize group size in order to detect a maximum number of individuals all while limiting the risk of false negatives?

The researchers also present an accurate method for measuring the proportion of individuals infected in the tested population (known as prevalence) which can guide the application of preventive measures against epidemic risk. According to their study, group testing is of particular interest because it can quickly and regularly evaluate the presence of SARS-COV-2 within “closed” communities (such as nursing homes or university residences).

Related Links:
Université Grenoble Alpes

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.